Article Text

Download PDFPDF

94 Fertility-sparing treatment in serous borderline ovarian tumorswith extra-ovarian invasive implants. An analysis from the MITO14 study database
  1. F Falcone1,
  2. M Malzoni2,
  3. G Cormio3,
  4. AM Perrone4,
  5. MG Ferrandina5,
  6. L Frigerio6,
  7. VDI Donato7,
  8. F Raspagliesi8,
  9. N Losito9 and
  10. S Greggi1
  1. 1Istituto Nazionale Tumori, IRCSS, ‘Fondazione G. Pascale’, Department of Gynecologic Oncology, Naples, Italy
  2. 2Center for Advanced Endoscopic Gynecologic Surgery, Endoscopica Malzoni, Avellino, Italy
  3. 3University of Bari ‘Aldo Moro’, Department of Biomedical Sciences and Human Oncology, Unit of Obstetrics and Gynecology, Bari, Italy
  4. 4IRCCS Azienda Ospedaliero-Universitaria di Bologna, Division of Oncologic Gynecology, Bologna, Italy
  5. 5Fondazione Policlinico Universitario A. Gemelli, IRCCS, Department of Woman and Child Health and Public Health, Rome, Italy
  6. 6ASST Papa Giovanni XXIII, Bergamo, Obstetrics and Gynecology Department, Bergamo, Italy
  7. 7Umberto I, ‘Sapienza’ University of Rome, Department of Maternal and Child Health and Urological Sciences, Rome, Italy
  8. 8Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Gynecologic Oncology, Milan, Italy
  9. 9Istituto Nazionale Tumori, IRCSS, ‘Fondazione G. Pascale’, Surgical Pathology Unit, Naples, Italy


Introduction/Background*Only 10–15% of serous borderline ovarian tumors (SBOT) have extra-ovarian invasive implants, and conservative treatments have been rarely reported. The MITO14 is a multi-institutional retrospective study conducted with the aim of systematically collecting data from consecutive BOT patients. The present analysis reports the oncological and reproductive outcomes of women with SBOT and invasive implants registered into the MITO14 database and conservatively treated between January 1995 and December 2019

Methodology Thirteen patients (FIGO2014 stage II-III SBOT with invasive implants) were recruited (table 1). Primary and secondary endpoints were, respectively, recurrence, pregnancy and live birth rates. Only patients undergoing fertility-sparing surgery (FSS) were included, while patients were excluded in case of: age >45 years; presence of second tumor(s) requiring therapy interfering with the treatment of BOT.

Result(s)*Median follow-up from primary cytoreduction was 144 months (range 23–217). Eleven patients (84.6%) experienced at least one recurrence (median time to first relapse 17 months, range 4–190), all of these undergoing secondary surgery (FSS in 7). Five patients attempted to conceive (at least one pregnancy in 3; at least one healthy child in 2). At the end of the observation period, 12 patients (92.3%) showed no evidence of disease and 1 (7.7%) was alive with disease (table 2).

Abstract 94 Table 1

Patient, tumor, and treatment related characteristics

Abstract 94 Table 2

Oncologic and reproductive outcomes

Conclusion*Despite the recurrence high rate, survival and pregnancy outcomes indicate that FSS could be considered in SBOT with invasive implants.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.